Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Understanding Bioeconomy Systems: Integrating Economic, Organisational and Policy Concepts Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

17. The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges

verfasst von : Walia Zahra, Sachchida Nand Rai, Hareram Birla, Saumitra Sen Singh, Hagera Dilnashin, Aaina Singh Rathore, Surya Pratap Singh

Erschienen in: Bioeconomy for Sustainable Development

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

The main challenge in today’s world to the healthcare system is the elevated occurrence of the neurodegenerative disorders. Progress in the field of bioinformatics and biomedical research has allowed us to understand the pathobiology of the neurodegenerative disorders in a detailed manner. The threat of these diseases increases with aging, and Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are the major ones affecting the public health and posing the higher economic burden. The research centers, pharmaceutical companies, and academic institutions are conducting research work in collaborations these days to enhance the development of new therapeutic strategies and develop novel drugs in a sustainable way. This can help in the development of safer therapies with reduced risk and can help in developing the authentic and evident biomarkers so that the disease can be diagnosed at early stages and treated accordingly. The advancement can therefore help in improving the quality of life of patients suffering from these debilitating neurodegenerative disorders and can also help in providing the job opportunities to the students interested in drug development program.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Function of the Medicinal Plants of the Mangroves in a Society of High Marginalization in Tabasco, Mexico
Nächstes Kapitel Conjugated Recombinant Proteins as Emerging New Drugs
Literatur
Agnati LF, Zoli M, Biagini G, Fuxe K (1992) Neuronal plasticity and ageing processes in the frame of the ‘red queen theory’. Acta Physiol Scand 145(4):301–309CrossRef
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P (2017) On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther 9(1):60CrossRef
Alzheimer’s Association (2018) Alzheimer’s disease facts and figures. Alzheimers Dement 14(3):367–429CrossRef
Bano D, Zanetti F, Mende Y, Nicotera P (2011) Neurodegenerative processes in Huntington’s disease. Cell Death Dis 2(11):e228CrossRef
Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312(5778):1389–1392CrossRef
Borras-Blasco J, Plaza-Macías I, Navarro-Ruiz A, Peris-Marti J, Anton-Cano A (1998) Riluzole as a treatment for amyotrophic lateral sclerosis. Rev Neurol (160):1021–1027
Brodaty H, Heffernan M, Kochan NA, Draper B, Trollor JN, Reppermund S, Slavin MJ, Sachdev PS (2013) Mild cognitive impairment in a community sample: the Sydney memory and ageing study. Alzheimer’s Dement. 1 9(3):310–317CrossRef
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 1 3(3):186–191CrossRef
Carter AJ, Donner A, Lee WH, Bountra C (2017) Establishing a reliable framework for harnessing the creative power of the scientific crowd. PLoS Biol 15(2):e2001387CrossRef
Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6(4):37CrossRef
Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K (2017) Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s Dement: Transl Res Clin Interv 3(3):367–384
Cummings J, Reiber C, Kumar P (2018) The price of progress: funding and financing Alzheimer’s disease drug development. Alzheimer’s Dement: Trans Res Clin Interv 4:330–343
Deb A, Thornton JD, Sambamoorthi U, Innes K (2017) Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 17(2):189–202CrossRef
Deflorio C, Onesti E, Lauro C, Tartaglia G, Giovannelli A, Limatola C, Inghilleri M, Grassi F (2014) Partial block by riluzole of muscle sodium channels in myotubes from amyotrophic lateral sclerosis patients. Neurol Res Int 2014:946073CrossRef
Delamarre A, Meissner WG (2017) Epidemiology, environmental risk factors and genetics of Parkinson’s disease. La Presse Med 46(2):175–181CrossRef
Deng Y, Xu Z, Xu B, Tian Y, Xin X, Deng X, Gao J (2009) The protective effect of riluzole on manganese caused disruption of glutamate–glutamine cycle in rats. Brain Res 1289:106–117CrossRef
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 1(47):20–33CrossRef
Domingo A, Klein C (2018) Genetics of Parkinson disease. Handb Clin Neurol 147:211–227 Elsevier
Dragojlovic N, Lynd LD (2014) Crowdfunding drug development: the state of play in oncology and rare diseases. Drug Discov Today 19(11):1775–1780CrossRef
Durães F, Pinto M, Sousa E (2018) Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11(2):44CrossRef
Fleming JJ (2015) The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation. Health Aff 34(2):271–276CrossRef
Gammon K (2014) Neurodegenerative disease: brain windfall. Nature 515(7526):299–300CrossRef
Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 10:499–502CrossRef
Gordon PH (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 4(5):295CrossRef
Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP (2006) The natural history of primary lateral sclerosis. Neurology 66(5):647–653CrossRef
Greenhalgh T, Ovseiko PV, Fahy N, Shaw S, Kerr P, Rushforth AD, Channon KM, Kiparoglou V (2017) Maximising value from a United Kingdom biomedical research Centre: study protocol. Health Res Policy Syst 15(1):70CrossRef
Harris BT (2014) Amyotrophic lateral sclerosis. In: Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms. Elsevier, WalthamCrossRef
Heinrich M (2010) Galanthamine from Galanthus and other Amaryllidaceae–chemistry and biology based on traditional use. Alkaloids Chem Biol 68:157–165. Academic PressCrossRef
Hurtado-Puerto AM, Russo C, Fregni F (2018) Alzheimer’s disease. In: Neuromethods. Humana Press, New York
Hwang JY, Aromolaran KA, Zukin RS (2017) The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci 18(6):347CrossRef
Keswani C, Bisen K, Singh SP, Singh HB (2017) Traditional knowledge and medicinal plants of India in intellectual property landscape. Med Plants 9(1):1–11
Kumar A, Singh A (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195–203CrossRef
Lawrence S (2017) Biotech's wellspring—a survey of the health of the private sector in 2016. Nat Biotechnol 35(5):413CrossRef
Lin JY, Xie CL, Zhang SF, Yuan W, Liu ZG (2017) Current experimental studies of gene therapy in Parkinson’s disease. Front Aging Neurosci 9:126CrossRef
Lo AW, Ho C, Cummings J, Kosik KS (2014) Parallel discovery of Alzheimer’s therapeutics. Sci Transl Med 6(241):241cm5CrossRef
Logroscino G, Traynor BJ, Hardiman O, Couratier P, Mitchell JD, Swingler RJ, Beghi E (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79(1):6–11CrossRef
Lu H, Le WD, Xie YY, Wang XP (2016) Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol 14(4):314–321CrossRef
MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983CrossRef
Martorell P, Hurd MD, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 368(14):1326–1334CrossRef
Matyus P, Dunkel P, Chai CL, Sperlagh B, Huleatt PB (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 21(9):1267–1308CrossRef
McColgan P, Tabrizi SJ (2018) Huntington’s disease: a clinical review. Eur J Neurol 25(1):24–34CrossRef
Mucke HA (2015) The case of galantamine: repurposing and late blooming of a cholinergic drug. Future Sci OA 1(4):FSO73CrossRef
Mulder DW, Kurland LT, Offord KP, Beard CM (1986) Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36(4):511–517CrossRef
Muller S, Weigelt J (2010) Open-access public-private partnerships to enable drug discovery – new approaches. IDrugs: Invest Drugs J 13(3):175–180
Murphy DG, Goldman M, Loth E, Spooren W (2014) Public-private partnership: a new engine for translational research in neurosciences. Neuron 84(3):533–536CrossRef
Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, Hensley K, Beal MF, Kiaei M (2009) Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 220(1):191–197CrossRef
Nguyen HHP, Weydt P (2018) Huntington disease. Med Genet 30(2):246–251
Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X (2013) Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci 70(24):4729–4745CrossRef
Parayath NN, Pawar G, Avachat C, Miyake MM, Bleier B, Amiji MM (2017) Neurodegenerative disease. In: Nanomedicine for inflammatory diseases. CRC Press, Boca Raton/London, pp 289–318CrossRef
Payami H (2017) The emerging science of precision medicine and pharmacogenomics for Parkinson’s disease. Mov Disord 32(8):1139–1146CrossRef
Perry JJ, Pratt AJ, Getzoff ED (2012) Amyotrophic lateral sclerosis: update and new developments. Degenerative Neurol Neuromuscul Dis 2012(2):1
Portilla L, L Rohrbaugh M (2014) Leveraging public private partnerships to innovate under challenging budget times. Curr Top Med Chem 14(3):326–329CrossRef
Ramsey BW, Nepom GT, Lonial S (2017) Academic, foundation, and industry collaboration in finding new therapies. N Engl J Med 376(18):1762–1769CrossRef
Reiman EM, Langbaum J, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN (2011) Alzheimer’s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26(s3):321–329CrossRef
Roberts R, Knopman DS (2013) Classification and epidemiology of MCI. Clin Geriatr Med 29(4):753–772CrossRef
Rowland LP (2001) How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 58(3):512–515CrossRef
Schumacher-Schuh AF, Rieder CR, Hutz MH (2014) Parkinson’s disease pharmacogenomics: new findings and perspectives. Pharmacogenomics 15(9):1253–1271CrossRef
Scott TJ, O’connor AC, Link AN, Beaulieu TJ (2014) Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci 1313(1):17–34CrossRef
Sidders B, Brockel C, Gutteridge A, Harland L, Jansen PG, McEwen R, Michalovich D, Seidel H, Weiss B, Williams-Jones B, Woodwark M (2014) Precompetitive activity to address the biological data needs of drug discovery. Nat Rev Drug Discov 13(2):83CrossRef
Singh HB, Jha A, Keswani C (eds) (2016a) Intellectual property issues in biotechnology. CABI, Wallingford. 304 pages, ISBN-13: 9781780646534
Singh HB, Jha A, Keswani C (2016b) Biotechnology in agriculture, medicine and industry: an overview. In: Singh HB, Jha A, Keswani C (eds) Intellectual property issues in biotechnology. CABI, Wallingford, pp 1–4CrossRef
von Campenhausen S, Winter Y, e Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K (2011) Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21(2):180–191CrossRef
Vradenburg G (2015) A pivotal moment in Alzheimer’s disease and dementia: how global unity of purpose and action can beat the disease by 2025. Expert Rev Neurother 15(1):73–82CrossRef
Wang J, Gu BJ, Masters CL, Wang YJ (2017) A systemic view of Alzheimer disease—insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 13(10):612CrossRef
Widdus R (2005) Public-private partnerships: an overview. Trans R Soc Trop Med Hyg 99(Supplement_1):S1–S8CrossRef
Yacoubian TA (2017) Drug discovery approaches for the treatment of neurodegenerative disorders. Academic Press/Elsevier, Amsterdam
Metadaten
Titel
The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges
verfasst von
Walia Zahra
Sachchida Nand Rai
Hareram Birla
Saumitra Sen Singh
Hagera Dilnashin
Aaina Singh Rathore
Surya Pratap Singh
Copyright-Jahr
2020
Verlag
Springer Singapore
Buch
Bioeconomy for Sustainable Development

Print ISBN: 978-981-13-9430-0

Electronic ISBN: 978-981-13-9431-7

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/978-981-13-9431-7_17